Statins and symptomatic chronic systolic heart failure

A post-hoc analysis of 5010 patients enrolled in Val-HeFT

Henry Krum, Roberto Latini, Aldo P. Maggioni, Inder Anand, Serge Masson, Elisa Carretta, Franco Ingrillì, Giacinto Pettinati, Robert Glazer, Gianni Tognoni, Jay Cohn

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: Statins prolong survival in patients at high risk for cardiovascular events, however little is known regarding their efficacy and safety in patients with established chronic heart failure (CHF). To address this, we retrospectively analyzed the Valsartan Heart Failure Trial (Val-HeFT) database to determine outcomes in CHF patients according to statin use at baseline. Methods: Demographic characteristics of patients receiving statins at baseline (n = 1602) were compared with those who were not (n = 3048). A multivariate Cox proportional hazards model, with death as outcome, was used to assess the impact of statin therapy, with adjustment made for baseline differences in relevant parameters. Results: Patients receiving statins at baseline were younger with fewer females, fewer in NYHA III-IV, more with an ischemic etiology, more diabetics, higher BMI, lower SBP, more on beta-blockers, but no difference in LVEF or ACEi use. Mortality over a mean 2-year follow-up was 17.9% on statins versus 20.3% without statins (p = 0.029). Cox-adjusted hazard ratio for statins was 0.81 [95% CI 0.70-0.94]. No statistically significant interaction was found between statins and valsartan for mortality. After 4 months, the only laboratory changes were a reduction in CRP and an attenuation of the rise in norepinephrine in the statin group. Conclusions: In a large, contemporary sample of patients with CHF, statin use appeared to be associated with a lower 2-year mortality. These findings suggest a prognostic benefit for statins in established CHF, however prospective data are required to definitively address this issue. Condensed abstract: We examined major cardiovascular outcomes in patients who were (n = 1602) and were not (n = 3048) receiving statins at baseline in the Val-HeFT cohort of patients with mild to moderate systolic chronic heart failure. Mortality was reduced in patients receiving statins compared to those who were not, without any significant interaction effect between statin treatment and valsartan. These findings suggest a prognostic benefit for statins in established heart failure, however prospective data are required to definitively address this issue.

Original languageEnglish
Pages (from-to)48-53
Number of pages6
JournalInternational Journal of Cardiology
Volume119
Issue number1
DOIs
Publication statusPublished - Jun 25 2007

Fingerprint

Valsartan
Systolic Heart Failure
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Heart Failure
Mortality

Keywords

  • Angiotensin receptor blockers
  • C-reactive protein
  • Heart failure
  • Mortality
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Statins and symptomatic chronic systolic heart failure : A post-hoc analysis of 5010 patients enrolled in Val-HeFT. / Krum, Henry; Latini, Roberto; Maggioni, Aldo P.; Anand, Inder; Masson, Serge; Carretta, Elisa; Ingrillì, Franco; Pettinati, Giacinto; Glazer, Robert; Tognoni, Gianni; Cohn, Jay.

In: International Journal of Cardiology, Vol. 119, No. 1, 25.06.2007, p. 48-53.

Research output: Contribution to journalArticle

Krum, H, Latini, R, Maggioni, AP, Anand, I, Masson, S, Carretta, E, Ingrillì, F, Pettinati, G, Glazer, R, Tognoni, G & Cohn, J 2007, 'Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT', International Journal of Cardiology, vol. 119, no. 1, pp. 48-53. https://doi.org/10.1016/j.ijcard.2006.07.106
Krum, Henry ; Latini, Roberto ; Maggioni, Aldo P. ; Anand, Inder ; Masson, Serge ; Carretta, Elisa ; Ingrillì, Franco ; Pettinati, Giacinto ; Glazer, Robert ; Tognoni, Gianni ; Cohn, Jay. / Statins and symptomatic chronic systolic heart failure : A post-hoc analysis of 5010 patients enrolled in Val-HeFT. In: International Journal of Cardiology. 2007 ; Vol. 119, No. 1. pp. 48-53.
@article{17028fbed7f1472d842d234c292527ea,
title = "Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT",
abstract = "Background: Statins prolong survival in patients at high risk for cardiovascular events, however little is known regarding their efficacy and safety in patients with established chronic heart failure (CHF). To address this, we retrospectively analyzed the Valsartan Heart Failure Trial (Val-HeFT) database to determine outcomes in CHF patients according to statin use at baseline. Methods: Demographic characteristics of patients receiving statins at baseline (n = 1602) were compared with those who were not (n = 3048). A multivariate Cox proportional hazards model, with death as outcome, was used to assess the impact of statin therapy, with adjustment made for baseline differences in relevant parameters. Results: Patients receiving statins at baseline were younger with fewer females, fewer in NYHA III-IV, more with an ischemic etiology, more diabetics, higher BMI, lower SBP, more on beta-blockers, but no difference in LVEF or ACEi use. Mortality over a mean 2-year follow-up was 17.9{\%} on statins versus 20.3{\%} without statins (p = 0.029). Cox-adjusted hazard ratio for statins was 0.81 [95{\%} CI 0.70-0.94]. No statistically significant interaction was found between statins and valsartan for mortality. After 4 months, the only laboratory changes were a reduction in CRP and an attenuation of the rise in norepinephrine in the statin group. Conclusions: In a large, contemporary sample of patients with CHF, statin use appeared to be associated with a lower 2-year mortality. These findings suggest a prognostic benefit for statins in established CHF, however prospective data are required to definitively address this issue. Condensed abstract: We examined major cardiovascular outcomes in patients who were (n = 1602) and were not (n = 3048) receiving statins at baseline in the Val-HeFT cohort of patients with mild to moderate systolic chronic heart failure. Mortality was reduced in patients receiving statins compared to those who were not, without any significant interaction effect between statin treatment and valsartan. These findings suggest a prognostic benefit for statins in established heart failure, however prospective data are required to definitively address this issue.",
keywords = "Angiotensin receptor blockers, C-reactive protein, Heart failure, Mortality, Statins",
author = "Henry Krum and Roberto Latini and Maggioni, {Aldo P.} and Inder Anand and Serge Masson and Elisa Carretta and Franco Ingrill{\`i} and Giacinto Pettinati and Robert Glazer and Gianni Tognoni and Jay Cohn",
year = "2007",
month = "6",
day = "25",
doi = "10.1016/j.ijcard.2006.07.106",
language = "English",
volume = "119",
pages = "48--53",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Statins and symptomatic chronic systolic heart failure

T2 - A post-hoc analysis of 5010 patients enrolled in Val-HeFT

AU - Krum, Henry

AU - Latini, Roberto

AU - Maggioni, Aldo P.

AU - Anand, Inder

AU - Masson, Serge

AU - Carretta, Elisa

AU - Ingrillì, Franco

AU - Pettinati, Giacinto

AU - Glazer, Robert

AU - Tognoni, Gianni

AU - Cohn, Jay

PY - 2007/6/25

Y1 - 2007/6/25

N2 - Background: Statins prolong survival in patients at high risk for cardiovascular events, however little is known regarding their efficacy and safety in patients with established chronic heart failure (CHF). To address this, we retrospectively analyzed the Valsartan Heart Failure Trial (Val-HeFT) database to determine outcomes in CHF patients according to statin use at baseline. Methods: Demographic characteristics of patients receiving statins at baseline (n = 1602) were compared with those who were not (n = 3048). A multivariate Cox proportional hazards model, with death as outcome, was used to assess the impact of statin therapy, with adjustment made for baseline differences in relevant parameters. Results: Patients receiving statins at baseline were younger with fewer females, fewer in NYHA III-IV, more with an ischemic etiology, more diabetics, higher BMI, lower SBP, more on beta-blockers, but no difference in LVEF or ACEi use. Mortality over a mean 2-year follow-up was 17.9% on statins versus 20.3% without statins (p = 0.029). Cox-adjusted hazard ratio for statins was 0.81 [95% CI 0.70-0.94]. No statistically significant interaction was found between statins and valsartan for mortality. After 4 months, the only laboratory changes were a reduction in CRP and an attenuation of the rise in norepinephrine in the statin group. Conclusions: In a large, contemporary sample of patients with CHF, statin use appeared to be associated with a lower 2-year mortality. These findings suggest a prognostic benefit for statins in established CHF, however prospective data are required to definitively address this issue. Condensed abstract: We examined major cardiovascular outcomes in patients who were (n = 1602) and were not (n = 3048) receiving statins at baseline in the Val-HeFT cohort of patients with mild to moderate systolic chronic heart failure. Mortality was reduced in patients receiving statins compared to those who were not, without any significant interaction effect between statin treatment and valsartan. These findings suggest a prognostic benefit for statins in established heart failure, however prospective data are required to definitively address this issue.

AB - Background: Statins prolong survival in patients at high risk for cardiovascular events, however little is known regarding their efficacy and safety in patients with established chronic heart failure (CHF). To address this, we retrospectively analyzed the Valsartan Heart Failure Trial (Val-HeFT) database to determine outcomes in CHF patients according to statin use at baseline. Methods: Demographic characteristics of patients receiving statins at baseline (n = 1602) were compared with those who were not (n = 3048). A multivariate Cox proportional hazards model, with death as outcome, was used to assess the impact of statin therapy, with adjustment made for baseline differences in relevant parameters. Results: Patients receiving statins at baseline were younger with fewer females, fewer in NYHA III-IV, more with an ischemic etiology, more diabetics, higher BMI, lower SBP, more on beta-blockers, but no difference in LVEF or ACEi use. Mortality over a mean 2-year follow-up was 17.9% on statins versus 20.3% without statins (p = 0.029). Cox-adjusted hazard ratio for statins was 0.81 [95% CI 0.70-0.94]. No statistically significant interaction was found between statins and valsartan for mortality. After 4 months, the only laboratory changes were a reduction in CRP and an attenuation of the rise in norepinephrine in the statin group. Conclusions: In a large, contemporary sample of patients with CHF, statin use appeared to be associated with a lower 2-year mortality. These findings suggest a prognostic benefit for statins in established CHF, however prospective data are required to definitively address this issue. Condensed abstract: We examined major cardiovascular outcomes in patients who were (n = 1602) and were not (n = 3048) receiving statins at baseline in the Val-HeFT cohort of patients with mild to moderate systolic chronic heart failure. Mortality was reduced in patients receiving statins compared to those who were not, without any significant interaction effect between statin treatment and valsartan. These findings suggest a prognostic benefit for statins in established heart failure, however prospective data are required to definitively address this issue.

KW - Angiotensin receptor blockers

KW - C-reactive protein

KW - Heart failure

KW - Mortality

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=34249687159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249687159&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2006.07.106

DO - 10.1016/j.ijcard.2006.07.106

M3 - Article

VL - 119

SP - 48

EP - 53

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -